Ipatasertib is an experimental cancer drug in development by Roche. It is a small molecule inhibitor of AKT, which is a key component of the PI3K/AKT/mTOR pathway. It was discovered by Array Biopharma and is currently in phase II trials for treatment of breast cancer.